OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral direct activator, OV4071There were no treatment-related laboratory findings, no ...
TAMPA, Fla. and LONDON, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology ...
News-Medical.Net on MSN
Aptamer Group and Alphazyme execute licensing agreement for synthetic aptamer-based enzyme modulation in hot-start PCR
Aptamer Group plc, a developer of synthetic oligonucleotide-based binding reagents for life sciences applications, and ...
Atomic-scale imperfections in graphene transistors generate unique wireless fingerprints that cannot be copied or predicted, ...
Underwater wireless power transfer is emerging as a key technology for enabling long-duration, maintenance-free operation of ...
TAMPA, Fla. and LONDON, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology ...
“Photon Design's next-generation, EPIPPROP simulator, will offer the flexibility to split waveguides, simulating this process ...
Learn more about whether Travere Therapeutics, Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, today ...
Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads today ...
-- First Patient Expected to be Dosed Next Week with Intranasal Foralumab -- PET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer's Patient on Leqembi (R) (Lecanemab) Anti-Amyloid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback